Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Income Before Tax
Profit after all operating and non-operating items but before income tax.
Apogee Therapeutics, Inc.NASDAQ: APGE
Income Before Tax · Q2 FY2026 · quarter ended Jun 2026
Income before tax remains negative
Q2 FY2026 income before tax was -$85.78M, compared with -$66.02M a year earlier. Trailing-twelve-month income before tax was -$294.09M.
Context
- Income before tax grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income before tax holds near -$85.78M or moves back toward the trailing-twelve-month quarterly average of -$73.52M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (255.57M) USD
- Year-over-year change
- -40.3%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (255.57M) | -40.3% |
| FY2024 | 2024-12-31 | (182.13M) | -116.9% |
| FY2023 | 2023-12-31 | (83.99M) | -111.1% |
| FY2022 | 2022-12-31 | (39.79M) | — |
Income Before Tax vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.8% is the 5th highest of 10, against a peer median of -34.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.2M USD | +114.5% | — | 2.4% | |
| LTM Jun 2026 | -$190.72M USD | +10.3% | — | 42.4% | |
| LTM Jun 2026 | -$226.48M USD | -52.3% | — | — | |
| LTM Sep 2026 | -$237.46M USD | -56.8% | — | 3851.1% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | -$242.79M USD | -34.4% | — | — |
| LTM Mar 2026 | -$249.37M USD | -13.3% | — | — | |
| LTM Jun 2026 | -$294.09M USD | -23.8% | — | — | |
| LTM Sep 2026 | -$429.51M USD | -38.7% | — | — | |
| LTM Mar 2026 | -$605.54M USD | -10.7% | — | 90.5% | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥1.2B CNY | -204.2% | — | 215.3% |
| Peer median (excluding APGE) | — | -34.4% | — | 90.5% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.42M |
| Gross Profit | 0 | 0 | 0 | (1.42M) |
| Gross Margin | — | — | — | — |
| Research & Development | 27.79M | 68.42M | 167.87M | 214.71M |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M | 70.88M |
| Operating Expenses | 30.73M | 93M | 216.87M | 284.18M |
| Depreciation & Amortization | 0 | 9.02M | 189K | 1.42M |
| EBITDA | (39.79M) | (74.97M) | (181.94M) | (254.15M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (30.73M) | (93M) | (216.87M) | (285.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 92K | 9.02M | 34.74M | 30.03M |
| Interest Expense | 9.15M | 0 | 0 | 0 |
| Other Income / Expenses | (9.06M) | 9.02M | 34.74M | 30.03M |
| Income Before Tax | (39.79M) | (83.99M) | (182.13M) | (255.57M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 18K | 278K |
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.79) | (1.66) | (3.30) | (4.22) |
| EPS (Diluted) | (0.79) | (1.66) | (3.30) | (4.22) |
| Weighted Avg Shares | 50.67M | 50.66M | 55.19M | 60.69M |
| Weighted Avg Shares (Diluted) | 50.67M | 50.66M | 55.19M | 60.69M |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.